The present issue of the Journal of Molecular Neuroscience, a most welcomed initiative of the guest editors, George Fink, Peng Lei, and Ashley Ian Bush, provides an excellent focus on various aspects of dementia, summarizing important findings and facing the future. A question frequently asked by lay audience is whether dementia equals Alzheimer's disease. Indeed, Alzheimer's disease is the most prevalent dementia, but as exemplified in the current issue, other pathologies also lead to dementia.
From the point of view of Alzheimer's disease and dementia, the Journal of Molecular Neuroscience provides a stage for global special issues (e.g., Gozes 2001; Sisodia and Tanzi 2001; Refolo and Fillit 2004b) , as well as for issues focusing on specific molecular targets, like tau Gozes 2002 ), or on the major Alzheimer's risk gene, apolipoprotein E (Gozes 2004; Refolo and Fillit 2004a) . Other important aspects of dementia are covered in special issues as well, for example, a focus on frontotemporal dementia (Ghetti 2011; Gozes 2011) . In general, neurodegeneration was recently covered in a meeting report as well as in an issue dealing with muscular atrophy (Pennuto and Gozes 2016) .
With the seminal findings of the Australian, Colin Masters, the first to complete the sequence of beta-amyloid, a main therapeutic target against Alzheimer's disease (Masters et al. 1985) , and the first to clone the amyloid protein precursor gene (Kang et al. 1987 ), a focus on dementia research emanating from Australia, is of great importance, paving the path to major future breakthroughs. Thus, this current issue is timely and focused.
Interestingly, a recent article published in the Nature (August 31, 2016) (Sevigny et al. 2016 ) addresses immunotherapy as a preventative disease modifying passive vaccination against Alzheimer's disease. This article addresses again the amyloid hypothesis as a driver of Alzheimer's disease. Indeed, the pathology of amyloid plaques is specific to Alzheimer's disease, with the familial form of the disease caused by mutations either in the amyloid precursor protein or in presenilin. However, presenilin presents the most mutations in familial Alzheimer's disease and may be associated with pathways other than the amyloid pathway (De Strooper 2007) . Furthermore, healthy individuals present amyloid plagues in their brains (e.g., (Kawas et al. 2013; Malishkevich et al. 2015) ). Previous clinical trials addressing Alzheimer's vaccination at the level of the amyloid peptide mostly failed, albeit showing varying degrees of clearance of the amyloid plague burden (e.g., (Salloway et al. 2014) ). The recent study differs from previous evaluations in that the antibodies are now targeting aggregated amyloid and probably recognizing soluble, toxic, aggregated amyloid in the patient brain. A further difference is that the current study is targeting a prodromal or very mildly affected population, showing a slowing of clinical decline as measured by the Clinical Dementia Rating-Sum of Boxes and Mini Mental State Examination scores, paralleling amyloid clearance. Indeed, other investigational drugs showed cognitive protection in this population (e.g., (Gozes et al. 2009; Ayton et al. 2013; Morimoto et al. 2013) ). The impact of tauopathy, a major hallmark of Alzheimer's disease and other neurodegeneration (Pachima et al. 2016) , is not directly addressed in the most recent study. However, an ongoing clinical trial (BIOGEN IDEC) may solve the mystery of Alzheimer's related amyloid vaccination in the fight against neurodegeneration and dementia affecting the elderly population. These studies would not have been possible without the pioneering original amyloid discoveries including the cutting-edge articles cited above (Masters et al. 1985) .
The current issue of the Journal of Molecular Neuroscience covers many aspects of dementia, as outlined in the BIntroduction^section to the issue (Bush et al. 2016) , and the more we understand, the better treatment we can give toward Alzheimer's disease and other dementias becoming only memories.
From the desk of the Editor-In-Chief.
